424 related articles for article (PubMed ID: 17054919)
1. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
3. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
[TBL] [Abstract][Full Text] [Related]
4. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
6. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice.
Lee S; Youn YS; Lee SH; Byun Y; Lee KC
Diabetologia; 2006 Jul; 49(7):1608-11. PubMed ID: 16586064
[TBL] [Abstract][Full Text] [Related]
7. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.
Youn YS; Chae SY; Lee S; Kwon MJ; Shin HJ; Lee KC
Eur J Pharm Biopharm; 2008 Mar; 68(3):667-75. PubMed ID: 17904340
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.
Chae SY; Chun YG; Lee S; Jin CH; Lee ES; Lee KC; Youn YS
J Pharm Sci; 2009 Apr; 98(4):1556-67. PubMed ID: 18704955
[TBL] [Abstract][Full Text] [Related]
9. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
10. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
[TBL] [Abstract][Full Text] [Related]
12. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
Youn YS; Lee KC
Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
15. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
[TBL] [Abstract][Full Text] [Related]
16. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 C-terminal structures affect its blood glucose lowering-function.
Li Y; Shi C; Lv Q; Zhang H; Li B; Bian G; Huang Q; Zhang W; Xue X; Ren X; Gao H; Sun C; Wang J; Zhang M
J Pept Sci; 2008 Jul; 14(7):777-85. PubMed ID: 18200618
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes.
Al-Omar MA; Al-Arifi MN
Saudi Med J; 2005 Oct; 26(10):1511-5. PubMed ID: 16228047
[TBL] [Abstract][Full Text] [Related]
20. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
